RxDoctor Payments Data

Obinna Mgbako, DPM

Podiatrist · Westfield, NJNPI 1023230679

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,203 of the $8,105 with a category attached, or 88.9%. 36 manufacturers reported payments, led by Stryker at 37.1% of the total. Among podiatrist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,105in general payments, 2019–2025

Across 224 payments — averaging $36.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$3K
  • Smith+Nephew$612
  • Next Science LLC$502
  • Seapearl East, Inc$460
  • Averitas Pharma Inc.$429
  • Integra Lifesciences Corporation$332
  • plus $3K from 30 others

What the payments were for

  • Travel & lodging$90211%
  • Food & beverage$7,20389%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,105 in reported general payments places this provider in the 90th percentile of 382 podiatrist providers in New Jersey.

See all podiatrist providers in New Jersey

Medicare billing

Part B allowed, 2024
$138,102
Medicare patients
282
Services billed
1,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole20$19,452
Mupirocin96$936
Ammonium Lactate39$582
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip27$419
Ketoconazole25$394
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$284
Pregabalin31$263
Gabapentin33$148
Clotrimazole14$138
Doxycycline Hyclate24$133
Tramadol Hcl37$131
Ciprofloxacin Hcl18$114
Meloxicam28$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$123$19,45220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 podiatrist providers in New Jersey.

Other podiatrist in Westfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →